C
Conrad J. Wong
Researcher at Eli Lilly and Company
Publications - 44
Citations - 2495
Conrad J. Wong is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Abstinence & Drug Abstinence. The author has an hindex of 26, co-authored 44 publications receiving 2337 citations. Previous affiliations of Conrad J. Wong include Johns Hopkins University School of Medicine & University of Kentucky.
Papers
More filters
Journal ArticleDOI
Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up.
TL;DR: Abstinence-contingent incentives significantly increased cocaine abstinence during treatment and 1 year of follow-up compared with noncontingents incentives.
Journal ArticleDOI
Community reinforcement therapy for cocaine-dependent outpatients.
Stephen T. Higgins,Stacey C. Sigmon,Conrad J. Wong,Sarah H. Heil,Gary J. Badger,Robert Donham,Robert L. Dantona,Stacey Anthony +7 more
TL;DR: Combining CRA with vouchers had therapeutic effects on substance abuse and psychosocial functioning during treatment and posttreatment follow-up in cocaine-dependent outpatients, although effects on cocaine use appear to be limited to the treatment period.
Journal ArticleDOI
Broad beneficial effects of cocaine abstinence reinforcement among methadone patients.
Kenneth Silverman,Conrad J. Wong,Annie Umbricht-Schneiter,Ivan D. Montoya,Ivan D. Montoya,Charles R. Schuster,Charles R. Schuster,Kenzie L. Preston +7 more
TL;DR: The results replicate the efficacy of cocaine abstinence reinforcement and show that it can have broad beneficial effects.
Journal ArticleDOI
Increasing opiate abstinence through voucher-based reinforcement therapy
Kenneth Silverman,Kenneth Silverman,Conrad J. Wong,Stephen T. Higgins,Robert K. Brooner,Ivan D. Montoya,Carlo Contoreggi,Annie Umbricht-Schneiter,Charles R. Schuster,Kenzie L. Preston +9 more
TL;DR: Overall, the study shows that voucher-based reinforcement contingencies can decrease opiate use in heroin dependent patients receiving methadone maintenance treatment.
Journal ArticleDOI
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Linda M. Rorick-Kehn,Jeffrey M. Witkin,Michael A. Statnick,Elizabeth L. Eberle,Jamie H. McKinzie,Steven D. Kahl,Beth M. Forster,Conrad J. Wong,Xia Li,Robert S. Crile,David B. Shaw,Allison E. Sahr,Benjamin L. Adams,Steven James Quimby,Nuria Diaz,Alma Jiménez,Concepción Pedregal,Charles H. Mitch,Kelly L. Knopp,Wesley H. Anderson,Jeffrey W. Cramer,David L. McKinzie +21 more
TL;DR: LY2456302 is a centrally-penetrant, potent, kappa-selective antagonist with pharmacokinetic properties favorable for clinical development and activity in animal models predictive of efficacy in mood and addictive disorders.